20.5 C
New York
Thursday, June 18, 2026

Tag: description

newssourceFORcompanyinformationcontent1marketreleases

Foran Reports Q2/25 Construction Progress at McIlvenna Bay

Reaffirms Mid-2026 Commercial Production Target Disciplined Underground Progress Reinforces 2026 Production Readiness Establishes At-The-Market Equity Program of up to C$50M /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES...

Man Group PLC : Form 8.3 – American Axle & Manufacturing Holdings, Inc.

FORM 8.3

Progress on share buyback programme

Progress on share buyback programme

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

Olin Announces Second Quarter 2025 Results

Highlights Second quarter 2025 net loss of ($1.3) million, or ($0.01) per diluted shareQuarterly adjusted EBITDA of $176.1 millionSecond quarter 2025 operating cash flow of...

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.

July 28, 2025
News Release

Q2 Sales and H1 2025 Financial Results

 

COURTOIS SA : Chiffre d’Affaires T2-2025

COURTOIS S.A.

GR Silver Mining Extends Silver Mineralization with Step-Out Drilling at San Marcial 11.9 m @ 226 g/t Ag Eq* including 0.9m @ 716 g/t...

VANCOUVER, BC, July 25, 2025 /CNW/ - GR Silver Mining Ltd. ("GR Silver Mining" or the "Company") (TSXV: GRSL) (OTCQB: GRSLF) (FRANKFURT: GPE) – is pleased...

Massage Envy Announces Scholarship Sweepstakes Winners

Eight monthly winners to receive $2,500 scholarship to attend massage school of their choice SCOTTSDALE, Ariz., July 25, 2025 /PRNewswire/ -- Massage Envy, a national...

Form 8.5 (EPT/RI) – Inspired Plc

FORM 8.5 (EPT/RI)

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”2

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Regenx Announces Delay in Filing of Annual Filings and Application for Management Cease Trade Order

EDMONTON, Alberta, July 24, 2025 (GLOBE NEWSWIRE) -- Regenx Tech Corp., (the "Corporation" or "Regenx") (CSE: RGX) (OTCQB: RGXT) (FSE: YRS WKN: A2DSW3) announces that as a result in delays in the completion of its audit, the Corporation will be unable to meet the filing deadline of July 29, 2025, for filing of the following continuous disclosure documents (collectively, the “Annual Filings”):

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDescription

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers